manag
acut
bronchiti
pneumonia
exacerb
underli
chronic
bronchiti
exclud
simpl
bronchiti
best
treat
symptomat
exacerb
chronic
bronchiti
treat
antibiot
broad
spectrum
antibiot
appropri
select
patient
manag
acut
bronchiti
pneumonia
exacerb
underli
chronic
bronchiti
exclud
simpl
bronchiti
best
treat
symptomat
exacerb
chronic
bronchiti
treat
antibiot
broad
spectrum
antibiot
appropri
select
patient
acut
bronchiti
character
inflamm
tracheobronchi
tree
may
infecti
noninfecti
etiolog
cough
without
fever
sputum
product
cold
symptom
common
manifest
cough
gener
acut
subacut
durat
last
less
two
three
week
us
upper
respiratori
tract
infect
uri
acut
bronchiti
two
five
common
condit
antibiot
prescrib
million
adult
primari
diagnosi
cold
uri
acut
bronchiti
bronchiti
result
antibiot
therapi
patient
underli
chronic
bronchiti
acut
bronchiti
acut
exacerb
chronic
bronchiti
aecb
estim
result
total
treatment
cost
billion
patient
year
age
million
year
age
cost
predominantli
hospit
consequ
acut
bronchiti
larg
depend
presenc
underli
lung
diseas
sever
specif
episod
host
factor
age
comorbid
etc
fact
like
pathogen
suscept
variou
antimicrobi
therapi
vari
differ
patient
popul
geograph
area
manuscript
numer
factor
review
includ
etiolog
acut
bronchiti
patient
without
underli
lung
diseas
current
evid
regard
antimicrobi
therapi
patient
role
antimicrobi
resist
particularli
patient
aecb
potenti
strategi
treat
patient
acut
bronchiti
much
avail
data
acut
bronchiti
collect
individu
without
signific
comorbid
much
follow
discuss
appli
care
patient
advanc
age
signific
comorbid
ill
etiolog
etiolog
agent
numer
rang
environment
irrit
viral
bacteri
pathogen
result
numer
studi
summar
tabl
acut
bronchiti
adult
without
underli
lung
diseas
usual
caus
viral
pathogen
frequent
identifi
agent
includ
influenza
parainfluenza
respiratori
syncyti
viru
coronaviru
adenoviru
rhinovirus
respiratori
syncyti
viru
receiv
increas
attent
attack
rate
approach
expos
adult
furthermor
cough
seen
major
infect
younger
older
adult
fact
elderli
patient
cough
seen
patient
rsv
infect
fever
seen
lower
respiratori
tract
involv
common
rale
wheez
importantli
pneumonia
uncommon
particularli
hospit
patient
influenza
infect
frequent
associ
cough
one
seri
patient
laboratoryconfirm
influenza
mean
age
year
cough
present
patient
bacteri
pathogen
unusu
although
studi
identifi
higher
frequenc
particularli
patient
previou
viral
respiratori
tract
infect
recent
studi
bacteri
pathogen
identifi
patient
frequent
isol
includ
pneumonia
h
influenza
catarrhali
importantli
seri
patient
evid
focal
abnorm
physic
examin
chest
radiograph
chang
consist
infect
atyp
pathogen
pneumonia
c
pneumonia
b
pertussi
identifi
vari
frequenc
tabl
variabl
report
seri
like
reflect
diagnost
criteria
util
season
geograph
epidem
natur
infect
cough
associ
pertussi
infect
particularli
interest
cough
quit
frequent
patient
infect
bordetella
pertussi
fact
us
center
diseas
control
prevent
case
definit
requir
day
cough
either
paroxysm
whoop
make
diagnosi
gener
adult
pertussi
associ
persist
cough
mean
durat
day
compil
rang
given
avail
literatur
diagnost
evalu
gener
evalu
patient
acut
bronchiti
exclud
condit
present
acut
cough
requir
uniqu
diagnost
therapeut
approach
exclud
pneumonia
key
compon
evalu
process
accuraci
patient
histori
physic
examin
evalu
patient
suspect
pneumonia
review
detail
presenc
purul
sputum
weakli
associ
presenc
radiograph
pneumonia
physic
find
fever
local
chest
find
abnorm
breath
sound
rale
gener
support
diagnosi
lack
abnorm
vital
sign
heart
rate
beatsmin
respiratori
rate
breathsmin
oral
temperatur
physic
examin
focal
consolid
decreas
likelihood
pneumonia
elderli
patient
diagnosi
particularli
problemat
pneumonia
may
present
atyp
symptom
includ
confus
failur
thrive
worsen
underli
chronic
condit
fall
although
fever
may
absent
physic
find
nonspecif
tachypnea
use
sign
patient
conclus
identif
physic
find
exhibit
signific
interobserv
disagr
use
chest
radiographi
consid
concern
condit
may
present
acut
cough
exclud
influenza
infect
import
diagnos
specif
antivir
therapi
demonstr
favor
affect
clinic
cours
particularli
start
earli
cours
ill
recent
seri
highlight
clinic
syndrom
suggest
influenza
infect
retrospect
pool
analysi
clinic
trial
zanamivir
patient
confirm
influenza
infect
recruit
fall
andor
winter
describ
presenc
cough
fever
demonstr
best
posit
predict
valu
diagnosi
influenza
posit
predict
valu
similar
result
report
smaller
studi
subject
mean
age
year
present
flulik
ill
presenc
cough
ci
fever
ci
predict
laboratori
confirm
influenza
infect
older
hospit
patient
complex
cough
temperatur
higher
ill
durat
seven
day
less
provid
best
discrimin
influenza
infect
older
patient
chronic
obstruct
pulmonari
diseas
enrol
influenza
vaccin
trial
laboratori
document
influenza
infect
associ
fever
myalgia
although
posit
predict
valu
symptom
cough
seen
laboratori
document
influenza
respiratori
ill
clearli
acut
cough
fever
set
known
commun
influenza
infect
rais
suspicion
etiolog
agent
patient
cough
clinic
set
may
bit
difficult
older
patient
underli
respiratori
diseas
cough
either
paroxysm
whoop
typic
adult
pertussi
night
time
worsen
also
quit
typic
major
studi
adult
confirm
durat
cough
prolong
greater
patient
experienc
cough
longer
three
week
mean
durat
cough
rang
day
diagnosi
made
cultur
andor
polymeras
chain
reaction
pcr
respiratori
secret
serolog
method
unfortun
clinic
featur
reliabl
identifi
pertussi
infect
exposur
someon
infect
organ
cough
variant
asthma
difficult
diagnost
exclus
gener
diagnosi
reserv
patient
cough
last
longer
week
typifi
airway
hyperreact
interestingli
protract
phase
acut
bronchiti
character
cough
often
sputum
product
appear
character
similar
abnorm
pulmonari
function
test
airflow
obstruct
note
adult
initi
present
one
seri
anoth
group
investig
document
persist
posit
histamin
challeng
studi
adult
six
week
diagnosi
uncompl
acut
bronchiti
like
patient
acut
bronchiti
pulmonari
function
abnorm
transient
small
fraction
patient
initi
acut
bronchiti
episod
may
repres
initi
present
asthma
fact
particip
one
seri
acut
bronchiti
exhibit
clinic
physiolog
evid
asthma
chronic
bronchiti
three
year
later
optim
treatment
acut
uncompl
bronchiti
optim
treatment
acut
bronchiti
result
expedi
cure
lowest
cost
therapi
least
number
advers
reaction
optim
therapi
vari
one
patient
popul
anoth
use
antimicrobi
therapi
patient
acut
bronchiti
without
underli
lung
diseas
common
sever
recent
studi
confirm
antibiot
prescrib
patient
uncompl
bronchiti
appar
antibiot
therapi
studi
like
patient
older
sick
longer
day
seen
urgent
care
clinic
recent
crosssect
studi
report
data
nation
ambulatori
medic
care
survey
conduct
broadspectrum
agent
quinolon
amoxicillinclavulon
gener
cephalosporin
azithromycin
clarithromycin
prescrib
patient
acut
bronchiti
multivari
analysi
prescript
broadspectrum
agent
seen
live
northeast
southern
us
patient
care
intern
medicin
physician
contrast
gener
famili
physician
black
nonhispan
patient
hmo
member
patient
without
insur
less
like
broadspectrum
agent
prescrib
although
antibiot
frequent
prescrib
indic
efficaci
remain
controversi
sever
recent
metaanalys
examin
effect
antibiot
therapi
summar
tabl
studi
examin
defin
acut
bronchiti
acut
cough
without
sputum
unfortun
exclus
pneumonia
underli
lung
diseas
vari
studi
seen
use
antibiot
patient
without
underli
lung
diseas
result
limit
benefit
assum
caveat
diagnosi
mention
earlier
care
consid
individu
patient
see
figur
summari
metaanalys
examin
role
antibiot
therapi
acut
uncompl
bronchiti
fahey
et
al
smucni
et
al
bent
et
al
evan
et
al
trial
includ
data
one
unpublish
studi
thu
number
patient
approxim
recent
systemat
review
examin
placebocontrol
trial
analyz
result
subgroup
smoker
lack
subgroup
report
smoker
preclud
metaanalysi
avail
exist
data
suggest
limit
benefit
antibiot
similar
smoker
nonsmok
given
small
clinic
benefit
potenti
antibiot
associ
advers
event
difficult
recommend
routin
use
antibiot
treat
patient
acut
bronchiti
underli
lung
diseas
patient
recent
exposur
someon
infect
pertussi
antibiot
therapi
may
warrant
decreas
shed
pathogen
spread
diseas
older
patient
immunocompromis
recommend
must
made
care
individu
approach
patient
particular
attent
diagnost
process
import
recent
sever
group
confirm
concert
effort
decreas
antibiot
prescript
case
acut
uncompl
bronchiti
quit
success
author
confirm
import
appropri
patient
physician
educ
importantli
subsequ
report
suggest
intervent
result
decreas
patient
satisfact
care
symptomat
therapi
uncompl
acut
bronchiti
remain
controversi
although
investig
suggest
bronchodil
improv
cough
acut
bronchiti
recent
systemat
review
literatur
suggest
littl
evid
avail
support
routin
use
adrenerg
agonist
adult
acut
cough
nevertheless
patient
evid
airflow
obstruct
wheez
physic
examin
airflow
obstruct
spirometri
posit
bronchoprovoc
test
may
experi
symptomat
relief
use
nonspecif
antituss
agent
remain
controversi
agent
appear
use
patient
chronic
cough
acut
cough
recent
multispecialti
panel
recommend
follow
principl
manag
patient
acut
bronchiti
provid
realist
expect
regard
typic
durat
symptom
day
refer
cough
chest
cold
rather
bronchiti
decreas
patient
expect
antibiot
efficaci
person
risk
unnecessari
antibiot
use
includ
resist
side
effect
drug
explain
patient
greater
select
requir
treatment
acut
cough
etiolog
contrast
uncompl
acut
bronchiti
patient
underli
chronic
bronchiti
acut
exacerb
attribut
bacteri
infect
episod
potenti
pathogen
bacteria
identifi
mani
copd
patient
baselin
aecb
confirm
bronchoscop
sampl
sever
group
thu
intracellular
haemophilu
influenza
identifi
bronchial
biopsi
sampl
acut
ill
patient
chronic
bronchiti
compar
stabl
patient
health
control
local
system
immun
respons
h
influenza
identifi
copd
patient
presenc
bacteri
pathogen
sputum
stabl
phase
bacteri
colon
associ
greater
aecb
frequenc
greater
declin
fev
link
bacteri
infect
aecb
came
recent
work
sethi
et
al
demonstr
likelihood
patient
report
aecb
relat
identif
new
strain
h
influenza
moraxella
catarrhali
streptococcu
pneumonia
sputum
rather
simpli
presenc
organ
recent
prospect
studi
patient
copd
confirm
dynam
bacteri
colon
chang
bacteri
speci
identifi
quantit
cultur
sputum
sampl
subject
grew
entir
differ
bacteri
speci
numer
time
point
cours
month
followup
interestingli
patient
chang
bacteri
speci
like
subsequ
experi
decrement
fev
numer
mechan
bacteria
may
relat
symptom
aecb
particularli
airway
inflamm
import
compon
diseas
patient
neutrophil
eosinophil
implic
aecb
data
support
role
cell
type
come
part
analysi
inflammatori
marker
sputum
compar
nonpurul
sputum
purul
sputum
contain
greater
concentr
neutrophil
chemoattract
ltb
neutrophil
marker
activ
includ
myeloperoxidas
mpo
neutrophil
elastas
ne
baselin
sputum
patient
frequent
exacerb
exhibit
increas
level
although
increas
number
sputum
inflammatori
cell
like
infect
import
trigger
airway
inflamm
copd
concentr
sputum
mpo
ne
ltb
colon
patient
correl
bacteri
count
bacteri
colon
associ
increas
sputum
level
tumor
necrosi
potent
proxim
stimulu
neutrophil
recruit
colon
bacteri
speci
appear
influenc
inflammatori
respons
greatest
respons
associ
pseudomona
aeruginosa
h
influenza
presenc
bacteri
pathogen
sputum
aecb
associ
higher
concentr
neutrophil
chemoattract
evid
neutrophil
degranul
concentr
ne
appear
highest
h
influenza
infect
h
influenza
also
elicit
product
cultur
epitheli
cell
final
serial
measur
patient
aecb
provid
support
import
alter
inflammatori
milieu
airway
patient
without
antitrypsin
defici
decreas
administr
antibiot
amoxicillin
cefuroxim
decreas
sputum
ltb
note
treatment
purul
aecb
cefuroxim
sever
line
evid
suggest
convent
bacteria
princip
culprit
episod
enumer
tabl
common
bacteria
isol
patient
pneumonia
h
influenza
catarrhali
enter
gramneg
rod
addit
sever
underli
pulmonari
diseas
patient
factor
like
affect
etiolog
agent
one
studi
patient
hospit
aecb
confirm
h
influenza
like
identifi
sputum
activ
smoker
ci
recent
studi
aecb
patient
found
patient
decreas
fev
predict
greater
likelihood
infect
enterobacteriaca
pseudomona
speci
h
influenza
data
complement
recent
studi
document
unsuspect
incid
asymptomat
bronchiectasi
ct
advanc
copd
role
microorgan
controversi
chlamydia
pneumonia
infect
detect
serolog
patient
aecb
although
accumul
data
viral
infect
import
trigger
aecb
uncertain
degre
viral
infect
trigger
bacteri
superinfect
interestingli
patient
aecb
relat
respiratori
viral
infect
demonstr
higher
symptom
score
onset
exacerb
take
longer
resolv
symptom
vs
day
one
trial
thu
wide
varieti
pathogen
respons
episod
acut
bronchiti
pathogen
identifi
differ
accord
presenc
sever
underli
pulmonari
diseas
unfortun
simpl
delin
etiolog
difficult
achiev
practic
diagnost
evalu
chronic
bronchiti
defin
clinic
presenc
chronic
product
cough
three
month
two
consecut
year
aecb
loos
defin
base
clinic
symptom
acut
worsen
breathless
cough
sputum
volum
sputum
purul
take
account
natur
fluctuat
symptom
feel
wellb
copd
patient
group
expert
defin
aecb
sustain
worsen
patient
condit
stabl
state
beyond
normal
daytoday
variat
acut
onset
necessit
chang
regular
medic
patient
underli
copd
prospect
studi
indic
episod
aecb
underreport
patient
need
lead
health
care
visit
given
inher
difficulti
diagnosi
pneumonia
highlight
earlier
surpris
chest
radiograph
found
identifi
signific
abnorm
sizeabl
minor
patient
present
aecb
three
observ
studi
identifi
abnorm
patient
although
spirometr
studi
loos
correl
likelihood
failur
episod
aecb
limit
valu
manag
specif
episod
aecb
optim
treatment
acut
exacerb
chronic
bronchiti
recent
comprehens
multispecialti
evid
base
review
literatur
address
manag
aecb
publish
clear
optim
manag
incorpor
multipl
therapeut
modal
patient
aecb
higher
likelihood
bacteri
etiolog
surpris
placebocontrol
trial
antibiot
aecb
suggest
modest
treatment
effect
saint
colleagu
perform
metaanalysi
nine
publish
trial
random
patient
exacerb
chronic
bronchiti
either
antibiot
therapi
placebo
investig
found
small
statist
signific
benefit
patient
given
antibiot
improv
peak
expiratori
flow
rate
pefr
lminut
ci
favor
antibiotictr
group
bach
et
al
perform
similar
analysi
placebo
control
trial
reach
similar
conclus
antibiot
offer
benefit
patient
aecb
two
recent
studi
shed
light
role
antibiot
one
studi
patient
aecb
sever
enough
requir
mechan
ventil
within
first
hour
admiss
document
decreas
hospit
mortal
need
addit
antibiot
icu
hospit
length
stay
patient
random
ofloxacin
versu
placebo
data
support
previou
find
suggest
sever
aecb
like
favor
respond
antimicrobi
therapi
separ
multicent
random
trial
amoxicillinclavulan
versu
placebo
confirm
greater
differenti
benefit
antibiot
therapi
aecb
patient
lower
baselin
fev
patient
group
sever
airflow
obstruct
mean
fev
predict
like
improv
resolv
symptom
antibiot
success
rate
placebo
treat
patient
diseas
sever
data
confirm
patient
sever
underli
airflow
obstruct
like
respond
antibiot
therapi
determin
individu
patient
like
requir
antibiot
therapi
aecb
remain
difficult
often
cite
individu
studi
evalu
efficaci
antibiot
patient
exacerb
copd
prospect
trial
anthonisen
et
al
group
random
patient
episod
aecb
antibiot
trimethoprimsulfamethoxazol
amoxicillin
doxycylin
stratifi
result
base
number
symptom
aecb
patient
least
two
cardin
symptom
increas
dyspnea
increas
sputum
product
andor
chang
sputum
color
experienc
benefit
antibiot
therapi
greatest
benefit
seen
patient
three
symptom
interestingli
individu
one
symptom
benefit
antibiot
therapi
thu
antibiot
therapi
like
advantag
patient
aecb
suffer
multipl
symptom
investig
suggest
approxim
exacerb
may
meet
criteria
recent
studi
evalu
impact
sputum
purul
note
patient
exacerb
mucoid
sputum
resolv
exacerb
without
antibiot
therapi
patient
purul
sputum
like
polymorphonuclear
cell
organ
sputum
patient
resolv
aecb
antibiot
therapi
data
suggest
new
purul
sputum
may
identifi
patient
like
benefit
antibiot
therapi
despit
guidelin
antibiot
therapi
fail
significantli
impact
symptom
approxim
patient
aecb
therapeut
failur
may
lead
impair
qualiti
life
increas
physician
visit
diagnost
test
hospit
day
lost
work
increas
health
care
cost
numer
author
suggest
stratifi
patient
likelihood
treatment
failur
earli
aecb
recurr
guidelin
center
identifi
featur
suggest
high
likelihood
infect
organ
cover
standard
antibiot
regimen
eg
p
aeruginosa
resist
gramneg
enter
bacteria
host
factor
predict
treatment
failur
addit
bacteri
resist
pattern
may
need
taken
consider
prior
initi
therapi
numer
author
examin
factor
predict
failur
therapi
aecb
ball
colleagu
examin
patient
aecb
identifi
coexist
cardiopulmonari
diseas
greater
four
respiratori
infect
preced
month
predict
failur
recov
treatment
retrospect
studi
patient
copd
use
home
oxygen
marker
diseas
sever
frequenc
previou
exacerb
featur
like
suggest
failur
relaps
within
four
week
therapi
chanc
failur
patient
four
exacerb
previou
month
larg
prospect
studi
identifi
greater
risk
treatment
failur
relaps
within
one
month
treatment
patient
ischem
heart
diseas
ci
wors
dyspnea
number
visit
previou
year
ci
studi
confirm
advanc
age
signific
impair
lung
function
poor
perform
statu
comorbid
condit
particularli
cardiovascular
independ
risk
factor
treatment
failur
patient
aecb
use
criteria
numer
guidelin
suggest
tailor
initi
antimicrobi
regim
individu
increas
risk
treatment
failur
see
tabl
note
earlier
patient
sever
lung
diseas
like
harbor
pathogen
p
aeruginosa
resist
first
line
antibiot
may
like
fail
therapi
first
line
antibiot
role
antimicrobi
resist
among
common
bacteria
pneumonia
h
influenza
catarrhali
treatment
failur
aecb
remain
uncertain
antimicrobi
resist
among
respiratori
pathogen
increas
past
decad
appear
relat
antimicrobi
util
among
pneumonia
isol
wide
variabl
penicillin
suscept
us
highest
percentag
suscept
strain
pacif
region
lowest
south
atlant
vitro
resist
macrolid
increas
past
sever
year
histor
activ
newer
gener
fluoroquinolon
eg
levofloxacin
moxifloxacin
gatifloxacin
gemifloxacin
excel
test
penicillin
sensit
resist
pneumonia
isol
fact
levofloxacin
moxifloxacin
recent
receiv
us
food
drug
administr
fda
approv
respiratori
infect
penicillin
nonsuscept
pneumonia
unfortun
increas
resist
fluoroquinolon
among
pneumonia
isol
recent
report
north
america
asia
pacif
region
importantli
casecontrol
studi
patient
levofloxacinresist
isol
isol
three
hospit
month
recent
publish
risk
factor
colon
levofloxacinresist
isol
includ
presenc
copd
exposur
fluoroquinolon
resist
also
seen
common
gramneg
respiratori
isol
h
influenza
catarrhali
overal
preval
product
note
recent
antimicrobi
surveil
program
rang
low
mid
although
rare
neg
ampicillin
resist
strain
report
amoxicillinclavulan
resist
strain
note
one
group
identifi
multipl
strain
nontyp
h
influenza
sputum
patient
chronic
obstruct
pulmonari
diseas
interestingli
isol
strain
vari
mic
includ
contain
strain
mic
cross
breakpoint
resist
although
catarrhali
isol
note
produc
sinc
first
isol
preval
product
risen
current
plateau
mid
high
rang
sever
type
vari
amount
substrat
produc
vari
substrat
affin
suscept
vari
surveil
studi
despit
worrisom
vitro
data
clinic
impact
antibiot
resist
remain
unclear
patient
aecb
date
studi
clearli
demonstr
aecb
patient
infect
resist
strain
wors
outcom
similar
patient
infect
suscept
bacteri
strain
suggest
bacteriolog
failur
associ
greater
likelihood
clinic
failur
patient
aecb
indirect
evid
support
relationship
antimicrobi
resist
clinic
failur
recent
suggest
one
group
retrospect
studi
patient
suffer
exacerb
antibiot
prescript
associ
lower
relaps
rate
subsequ
two
week
vs
patient
treat
amoxicillin
experienc
highest
relaps
rate
author
hypothes
higher
failur
rate
may
relat
antimicrobi
resist
although
microbiolog
data
report
two
recent
similar
analys
confirm
differ
failur
rate
associ
differ
antibiot
util
patient
aecb
examin
prospect
random
studi
compar
variou
antimicrobi
agent
fail
reveal
strong
relationship
microbiolog
erad
antimicrobi
suscept
clinic
failur
although
sever
studi
confirm
decreas
bacteriolog
erad
organ
vitro
resist
antimicrobi
administ
clinic
failur
consist
report
compel
report
confirm
relationship
antimicrobi
resist
impair
clinic
outcom
identifi
nosocomi
outbreak
fluoroquinolon
resist
pneumonia
infect
hospit
ward
ciprofloxacin
frequent
use
treat
lower
respiratori
tract
infect
thirteen
patient
ward
experienc
failur
treatment
aecb
importantli
bacteriolog
erad
p
aeruginosa
aecb
studi
vari
potenti
antimicrobi
treatment
stratif
acut
bronchiti
addit
data
requir
clarifi
whether
outcom
wors
aecb
patient
infect
due
resist
organ
data
support
stratifi
treatment
aecb
recent
report
grossman
et
al
report
result
prospect
studi
patient
chronic
bronchiti
least
three
exacerb
per
year
present
moder
sever
episod
aecb
random
ciprofloxacin
usual
antibiot
defin
antibiot
quinolon
overal
differ
treatment
strategi
howev
patient
risk
factor
moder
sever
bronchiti
greater
four
aecb
previou
year
use
ciprofloxacin
led
improv
clinic
outcom
higher
qualiti
life
lower
overal
cost
separ
studi
destach
et
al
retrospect
review
result
therapi
exacerb
patient
follow
pulmonari
specialti
clinic
antibiot
util
segreg
three
categori
firstlin
agent
amoxicillin
cotrimazol
erythromycin
tetracyclin
secondlin
agent
cephradin
cefuroxim
cefaclor
cefprozil
thirdlin
agent
coamoxiclav
azithromycin
ciprofloxacin
patient
treat
firstlin
agent
compar
third
line
agent
like
fail
therapi
vs
p
requir
hospit
within
two
week
vs
p
thu
expens
overal
fact
overal
cost
higher
agent
despit
lower
pharmaci
acquisit
cost
subsequ
analysi
investig
corrobor
earlier
find
data
support
similar
analysi
differ
group
potenti
system
stratifi
patient
likelihood
treatment
failur
enumer
tabl
clearli
addit
data
requir
better
defin
role
treatment
stratif
aecb
patient
inhal
agonist
anticholinerg
agent
document
efficaci
reliev
obstruct
aecb
magnitud
improv
vari
studi
rang
fev
fvc
period
minut
evid
base
review
conclud
shortact
agonist
anticholinergictyp
inhal
bronchodil
compar
effect
spirometri
greater
treatment
effect
parent
administ
bronchodil
combin
anticholinerg
block
drug
potenti
increas
therapeut
benefit
evid
util
ad
methylxanthin
inhal
bronchodil
also
conflict
high
incid
advers
reaction
make
difficult
recommend
routin
use
copd
exacerb
review
six
random
placebocontrol
trial
suggest
short
cours
system
steroid
improv
pulmonari
function
decreas
relaps
rate
aecb
similar
conclus
reach
recent
systemat
review
perus
trial
provid
relev
clinic
insight
largest
trial
random
patient
veteran
affair
medic
center
placebo
one
two
steroid
regimen
solumedrol
mgday
three
day
follow
either
day
week
taper
corticosteroid
group
associ
faster
improv
fev
lower
number
treatment
failur
shorter
length
stay
steroid
treat
patient
also
like
experi
complic
treatment
hyperglycemia
common
recent
studi
random
patient
hospit
aecb
methylprednisolon
mgkg
day
follow
either
steroid
taper
complet
day
patient
treat
longer
cours
experienc
greater
improv
fev
uk
investig
random
patient
admit
aecb
smaller
dose
prednison
mg
daili
day
versu
placebo
treat
prednison
experienc
faster
greater
improv
fev
predict
predict
placebo
vs
predict
predict
prednison
p
median
length
stay
also
shorter
steroid
treat
group
day
vs
day
p
interestingli
differ
percent
predict
fev
six
week
follow
two
group
corticosteroid
seem
benefici
treatment
hospit
patient
copd
exacerb
although
optim
dose
durat
therapi
known
moder
dose
approxim
mgday
period
approxim
week
seem
reason
inhal
corticosteroid
util
altern
oral
corticosteroid
treatment
aecb
maltai
et
al
random
patient
placebo
nebul
budesonid
mg
oral
prednison
mg
activ
treatment
arm
greater
improv
fev
compar
placebo
although
differ
budesonid
oral
prednison
incid
seriou
advers
event
similar
group
although
patient
oral
prednison
group
experienc
higher
incid
hyperglycemia
studi
requir
better
defin
role
inhal
corticosteroid
manag
patient
aecb
acut
bronchiti
common
condit
exist
data
strongli
support
routin
use
antimicrobi
agent
patient
bronchiti
underli
chronic
lung
diseas
older
patient
immunocompromis
individu
decis
import
exclus
pneumonia
altern
diagnosi
particularli
press
patient
patient
underli
obstruct
lung
diseas
chronic
bronchiti
experienc
aecb
evid
antibiot
use
establish
numer
control
trial
antimicrobi
agent
appear
indic
particularli
patient
suffer
multipl
symptom
prior
prescrib
broadspectrum
antibiot
patient
acut
bronchiti
howev
vital
clinician
consid
extent
underli
lung
diseas
medic
condit
extent
symptom
antimicrobi
resist
pattern
geograph
area
ct
